Veulemans Verena, Afzal Shazia, Ledwig Paul, Heiss Christian, Busch Lucas, Sansone Roberto, Soetemann Dagmar B, Maier Oliver, Kleinebrecht Laura, Kelm Malte, Zeus Tobias, Hellhammer Katharina
1 Division of Cardiology, Pulmonary Diseases, Vascular Medicine, Medical Faculty, University Düsseldorf, Germany.
a These authors contributed equally to this paper.
Vasa. 2018 Aug;47(5):393-401. doi: 10.1024/0301-1526/a000712. Epub 2018 Jun 28.
Vascular access site-related complications are frequent in the context of transfemoral transcatheter aortic valve replacement (TAVR). The implantation of a covered stent graft is an effective treatment option for bleeding control. However, the external iliac and common femoral arteries are exposed to flexion of the hip joint. Therefore, stent compression and stent/strut fractures may occur, facilitating stent occlusion.
In all 389 patients who received transfemoral TAVR from 2013-2015 at the Düsseldorf Heart Centre, we monitored the management of vascular access site-related complications. Our analyses focused on immediate technical success and bleeding control, primary patency, and the occurrence of stent/strut fractures after six to 12 months of follow-up.
Vascular access site-related complications occurred in 13 % (n = 51), whereof in 10 patients, the bleeding was successfully managed by prolonged compression. In 40 out of 51 patients, a covered stent graft was implanted in the common femoral artery, leading to 100 % immediate bleeding control. After a mean follow-up of 334 ± 188 days, 28 stents out of 29 patients with completed follow-up (excluding e. g. death) were without flow-limiting stenosis (primary patency 97 %) or relevant stent compression (diameter pre/post 8.6/8.1 mm, p = 0.048, late lumen loss 1.1 ± 0.2 mm, mean flow velocity 92 ± 34 cm/s). In four asymptomatic patients, stent/strut fractures were detected (14 %) without flow-limiting stenosis.
The implantation of a covered stent graft is highly effective and safe to control vascular access site-related complications after TAVR. Stent/strut fractures in the flexible segment of the common femoral artery may occur, as consequently verified by X-ray visualization, but show no impairment on flow or clinical parameters after six to 12 months.
在经股动脉经导管主动脉瓣置换术(TAVR)中,血管穿刺部位相关并发症很常见。植入覆膜支架移植物是控制出血的有效治疗选择。然而,髂外动脉和股总动脉会受到髋关节屈曲的影响。因此,可能会发生支架压缩和支架/支柱骨折,从而导致支架闭塞。
在2013年至2015年于杜塞尔多夫心脏中心接受经股动脉TAVR的389例患者中,我们监测了血管穿刺部位相关并发症的处理情况。我们的分析重点在于即刻技术成功和出血控制、原发性通畅率以及随访6至12个月后支架/支柱骨折的发生情况。
13%(n = 51)的患者发生了血管穿刺部位相关并发症,其中10例患者通过延长压迫成功控制了出血。51例患者中有40例在股总动脉植入了覆膜支架移植物,即刻出血控制率达100%。在平均随访334±188天后,29例完成随访的患者(不包括例如死亡患者)中有28个支架没有限流性狭窄(原发性通畅率97%)或相关的支架压缩(直径术前/术后8.6/8.1 mm,p = 0.048,晚期管腔丢失1.1±0.2 mm,平均流速92±34 cm/s)。在4例无症状患者中检测到支架/支柱骨折(14%),但没有限流性狭窄。
植入覆膜支架移植物在控制TAVR术后血管穿刺部位相关并发症方面非常有效且安全。股总动脉可弯曲段可能会发生支架/支柱骨折,X线显影证实了这一点,但在6至12个月后对血流或临床参数没有影响。